OBIZUR

ਉਤਪਾਦ ਝਲਕ

About OBIZUR

OBIZUR is a recombinant porcine sequence antihemophilic factor indicated for the treatment of bleeding episodes in adults with acquired hemophilia A. This medicine works by replacing the missing factor VIII, a protein necessary for blood clotting, which is deficient in individuals with hemophilia A. OBIZUR is administered intravenously and is designed to temporarily increase the levels of factor VIII, thereby promoting blood clotting and reducing the risk of bleeding complications.

Key Benefits & Uses

• Treatment of bleeding episodes in adults with acquired hemophilia A
• Temporary replacement of factor VIII to promote blood clotting
• Reduction of the risk of bleeding complications in individuals with acquired hemophilia A

Active Ingredient & Action

ANTIHEMOPHILIC FACTOR (RECOMBINANT) PORCINE SEQUENCE, the active ingredient in OBIZUR, works by mimicking the natural factor VIII in the body, facilitating the blood clotting process. This recombinant factor VIII is produced through genetic engineering and has a similar structure and function to the human factor VIII, allowing it to effectively replace the missing protein in individuals with acquired hemophilia A.

Important Notes

It is essential to follow the dosage and administration instructions provided by a healthcare professional when using OBIZUR. Individuals with a history of hypersensitivity to factor VIII or porcine proteins should exercise caution. Additionally, OBIZUR should only be administered in a clinical setting where appropriate medical care is available in case of an adverse reaction. Regular monitoring of factor VIII levels and adjustment of the dosage as needed is crucial for optimal treatment outcomes.